NEWS
Cortex Reports Third Quarter Operating Results
Cortex Announces Second Private Placement with Samyang
Servier Exercises Option to Cortex’s Ampakine® CX1632, an Innovative Compound in Clinical Development for Alzheimer’s Disease
Cortex Announces Revised Date for CEO Presentation at Rodman & Renshaw’s 13th Annual Healthcare Conference on September 12, 2011
Cortex Receives U.S. Patent for the use of Ampakine Molecules to Treat Respiratory Depression
Cortex Reports Second Quarter Operating Results
Cortex Enters into New Agreement with Servier
Cortex Reports First Quarter Operating Results
Cortex Receives Granted US Patent for its Lead AMPAKINE® Molecule Cx1739
Cortex Reports Fourth Quarter and Year End Operating Results
Cortex Reacquires all Ampakine® Compounds, Related Patents and Exclusive Global Rights for Respiratory Depression from Biovail
Cortex’s CEO to Present at the Roth Capital Partners 23rd Annual Orange County Growth Stock Conference
Cortex’s Ampakine CX1739 Improves Respiratory Parameters In Obstructive Sleep Apnea Patients
Cortex Reports Third Quarter 2010 Operating Results
First Joint Cortex-Servier High-Impact Ampakine Compound Moves into Phase I Clinical Studies
Cortex Obtains Exclusive Worldwide Rights for the Combination of AMPAKINE® and mGluR5 Compounds for the Treatment of Fragile X
Cortex Regains Rights to Develop its AMPAKINE Compounds to treat Depression and Schizophrenia
Cortex’s CEO to Present at Rodman & Renshaw’s 12th Annual Healthcare Conference on September 13, 2010
Cortex Reports Second Quarter Operating Results
Cortex Receives Funding from The Michael J. Fox Foundation to discover drug candidates for Parkinson’s disease
Cortex Reports First Quarter Operating Results
Cortex To Hold Annual Shareholder Meeting on May 19 at Marriott Newport Beach Hotel in Newport Beach, CA
Cortex Reports Fourth Quarter and Year End Operating Results
Cortex Sells Selected Ampakine Compounds and Rights to Respiratory Depression Indication to Biovail
Cortex Announces $1.5 Million Private Placement
|